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Abstract
Diet has been investigated in relation to its ability to promote cognitive function. However, evidence is currently limited and has rarely been
systematically reviewed, particularly in a mild cognitive impairment (MCI) population. This review examined the effect of diet on cognitive
outcomes in MCI patients. A total of five databases were searched to find randomised controlled trial (RCT) studies, with diet as the main focus,
in MCI participants. The primary outcome was incident dementia and/or Alzheimer's disease (AD) and secondary outcomes included
cognitive function across different domains using validated neuropsychological tests. Sixteen studies met the inclusion criteria. There was a
high degree of heterogeneity relating to the nature of the dietary intervention and cognitive outcomes measured, thus making study
comparisons difficult. Supplementation with vitamin E (one study, n 516), ginkgo biloba (one study, n 482) or Fortasyn Connect (one study, n
311) had no significant effect on progression from MCI to dementia and/or AD. For cognitive function, the findings showed some
improvements in performance, particularly in memory, with the most consistent results shown by B vitamins, including folic acid (one study, n
266), folic acid alone (one study, n 180), DHA and EPA (two studies, n 36 and n 86), DHA (one study, n 240) and flavonol supplementation
(one study, n 90). The findings indicate that dietary factors may have a potential benefit for cognitive function in MCI patients. Further well-
designed trials are needed, with standardised and robust measures of cognition to investigate the influence of diet on cognitive status.
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Cognitive impairment poses a major global public health chal-
lenge due to increasing prevalence in line with population
ageing(1). The transition from mild cognitive impairment (MCI)
through to the various forms of dementia, such as Alzheimer’s
disease (AD), is one of the costliest burdens on health service
delivery(2). The National Institute for Aging-Alzheimer’s
Association (NIA-AA) developed core clinical criteria to
inform the diagnosis of MCI(3). This identifies that a person
with MCI should display a change in cognition, expressed
through personal concern or identification from a physician. In
addition, individuals should display a lower performance in at
least one cognitive domain than that expected for their age and
education, over a period of time. Such domains are memory,
executive function, attention, visuospatial skills and language.
Finally, individuals with MCI may have slight problems with
complex daily tasks, however, generally live an independent
lifestyle with minimal assistance(3). MCI is described as a
transitional stage between the expected cognitive decline of
normal ageing and that of dementia(4). Furthermore, it has been
estimated that 46% of MCI patients develop dementia within 3
years from diagnosis(5). Therefore, it is critical to identify
effective interventions that can protect against cognitive decline
in this vulnerable high risk group(6).
Despite pharmacological advances, there are no effective
treatments to delay or reverse cognitive impairment. The
inflammatory mechanisms and oxidative stress involved in the
aetiology of cognitive decline and dementia(7), indicates a
potential role for nutrition in its prevention(8). Furthermore,
processes such as neurogenesis and neuronal connectivity
involved in the function of the brain are influenced by dietary
components(9,10). The role of nutrition in cognitive health
outcomes has been examined in terms of a range of nutrients/
dietary patterns, investigating the role that single nutrients, such
as n-3 PUFA(7), as well as whole foods/diet interventions, such
as the Dietary Approaches to Stop Hypertension (DASH)
diet(11), a ketogenic diet(12) or the Mediterranean diet(13) may
Abbreviations: AD, Alzheimer’s disease; GI, glycaemic index; HF, high flavonol; HR, hazard ratio; LF, low flavonol; MCI, mild cognitive impairment; MMSE, Mini
Mental State Examination; RCT, randomised controlled trial.
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have, particularly in relation to their effect on reducing
inflammation and oxidative stress(14–16). It has been suggested
that, although investigations into single nutrients have
importance from a mechanistic point of view, studies which
provide whole-diet analysis acknowledge that, in everyday
situations, foods are consumed in complex combinations and
may be a more representative approach to measure the effect of
diet on cognition(17). Furthermore, ensuring older adults with
MCI stay physically active could have beneficial effects on
cognition(18,19), alongside engaging in cognitive training
strategies to boost cognitive function. This involves a variety
of either computerised or hand-written techniques to enhance
memory, language and attention(20). However, the available
research in this area is variable, with a lack of specific studies in
MCI(6).
Ultimately, there is a need for this systematic review to
examine what is known to date about the role of diet on cog-
nitive health, either independently or in conjunction with other
lifestyle modifications, specifically in a MCI population. To our
knowledge, the effect of dietary interventions on cognitive
health outcomes, particularly in high risk populations, like MCI
has not been previously systematically reviewed and therefore
this has the potential to establish the evidence base for possible
management strategies and also define the scope for future
research, if required. Thus, the aim of this systematic review
was to examine the effect of diet, either alone or in combination
with lifestyle and/or cognitive strategies, on cognitive health
outcomes in patients with MCI.
Methods
The methods for this systematic review were based on the
Centre for Reviews and Dissemination guidance for undertaking
systematic reviews in health care(21) and the review
protocol was registered with PROSPERO (PROSPERO 2017:
CRD42017067267). To be included in this review, the article
had to be a randomised controlled trial (RCT) design,
conducted in patients with MCI and with diet as the main
focus of the intervention. Pilot studies were excluded when a
paper clearly stated that the research was a ‘pilot study’.
Interventions could focus on diet alone (a dietary pattern or
dietary supplements) or in combination with lifestyle and/or
cognitive strategies. An overview of the inclusion and exclusion
criteria is provided in Table 1. Incident dementia or AD was the
primary outcome measure. Secondary outcomes included overall
cognitive function or specific cognitive domains such as memory,
executive function, language, attention or visuospatial skills
measured using validated neuropsychological tests, for example,
Mini Mental State Examination (MMSE), Cambridge Cognition
Examination or Repeatable Battery for the Assessment of
Neuropsychological Status.
Study identification
A comprehensive literature search was undertaken in June 2016
using Ovid MEDLINE, EMBASE, PsycINFO, Web of Science
and Scopus. A suitable search strategy was devised considering
key terms used in associated reviews relating to ‘diet’, ‘lifestyle’,
‘cognitive strategies’, ‘cognition’ and ‘behaviour change’. Stu-
dies were restricted to English Language and similar search
terms were used in each database. This detailed search strategy
was developed in Ovid MEDLINE (online Supplementary Table
S1) and this strategy was tailored for the other databases. The
literature search was repeated in November 2016 and March
2018 to identify new publications. The reference lists of articles
and other relevant systematic reviews were screened for
potential trials not identified by the electronic search.
Data extraction
Titles and abstracts of potentially eligible studies were
screened by the first author (A. M. M.). Any articles not
meeting the inclusion criteria were excluded at this stage. Full
text articles were obtained for the remaining studies and the
study methodology was further assessed for eligibility (A. M.
M.). Any queries with regards to inclusion of articles were
Table 1. An overview of the inclusion and exclusion criteria for this systematic review
Inclusion criteria Exclusion criteria
Study design Randomised controlled trial Observational study design; pilot studies, when a paper clearly
stated that the research was a ‘pilot study’
Intervention Dietary intervention either diet alone (a dietary pattern or
dietary supplements) or in combination with lifestyle and/or
cognitive strategies
Medical type intervention in conjunction with either a diet/lifestyle/
cognitive intervention with undifferentiated results
Control Control interventions that were not expected to have specific
risk-modifying effects; control arms would typically involve
no intervention, usual diet or placebo
Studies with no comparator, placebo or control
Diagnosis of MCI Diagnosis of MCI was necessary by a medical physician or
according to internationally accepted and validated
classifications or criteria
‘Memory problems’ or ‘self-reported memory complaints’ and no
clear diagnosis of MCI; a diagnosis of dementia or any other form
of cognitive impairment other than MCI, unless results for MCI
participants were presented separately; ‘cognitively healthy adults’
Participants Community dwelling participants; no restrictions made
based on sex or age
Individuals who were hospitalised, in a rehabilitation or long-term care
facility; participants with psychiatric problems, for example,
depression or any significant medical comorbidity, or history of, a
comorbid condition that may alter performance on cognitive tests,
for example, stroke, head injury, Parkinson’s disease and learning
disability
MCI, mild cognitive impairment.
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discussed among the research team (C. T. M., J. V. W., B. M.
and M. C. M.). A data extraction form was generated to sum-
marise the key characteristics of the included articles,
extracting information on participant, intervention, and
methodological characteristics and cognitive outcome results.
Data was extracted for the primary and secondary outcomes as
stated previously. Information on quality of life and number of
participants experiencing one or more serious adverse events
was also extracted when provided in papers in addition to the
primary and secondary outcomes mentioned. Where studies
included validated biomarkers (e.g. structural MRI or amyloid
imaging) secondary to cognitive outcome measures, these data
were also extracted. The extraction was undertaken by the first
author (A. M. M.) and this was independently checked by the
second author (C. T. M.) and both reviewers discussed any
discrepancies as required.
Quality assessment
The methodological quality of the included studies was asses-
sed using the Jadad scale(22). This scale has been widely used to
assess the quality of RCT included in systematic reviews with
regards to randomisation procedures, double blinding and
participant withdrawals. A score of 1 was allocated for each
‘yes’ answer to the following three questions:
(1) Was the study described as randomised?
(2) Was the study described as double blind?
(3) Was there a description of withdrawals and drop outs?
An additional score of 1 was awarded if;
(4) The randomisation process was described and
appropriate
(5) The method of double blinding was described and
appropriate.The maximum possible score was 5(22).
The riskof biaswas assessedusing theCochrane classification(23).
Each study was assessed for the following (where appropriate): (1)
selection bias; (2) performance bias; (3) detection bias; (4) attrition
bias and (5) reporting bias. Individual studies were assessed as
either low, high or uncertain risk for the adequacy of the stated
variables.
Data analysis
The data collected were expected to display a high degree of
heterogeneity, therefore quantitative synthesis was unsuitable.
The results were summarised using narrative synthesis and
presented in tables.
Results
The systematic search in June 2016 generated a total of 2130
articles (2108 through database searches and twenty-two
through searches of reference lists). Following the removal of
650 duplicates, 1480 articles were screened for eligibility by
examining their titles and abstracts. This process excluded 1447
studies and the full texts of thirty-three papers were obtained;
twenty-two articles were excluded for the reasons outlined
in Fig. 1. Following a second (November 2016) and third
(March 2018) literature search, five further studies were iden-
tified that met the inclusion criteria and so sixteen studies were
included. As per the review protocol, the results have been
First search (June 2016):
Records identified 
through database 
searching = 2108
Additional records
identified through other
sources = 22
Records after duplicates removed = 1480
Titles and abstracts
screened = 1480
Records excluded =
1447
Full text articles assessed
for eligibility = 33
Full text articles excluded
= 22 with reasons;
cognitive outcomes as
defined by inclusion
criteria not measured
(n 7), not MCI
participants (n 4), no
differentiated subgroup
analysis (n 3),
institutionalised patients
(n 1), article in chinese
(n 3), pilot study (n 1),
no clear diagnosis of MCI
(n 2), participants with
depression (n 1)
Studies included in
analysis = 11
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Second search (Nov 2016):
Records identified through 
database searching = 201
Records after duplicates removed = 168
Titles and abstracts
screened = 168
Records excluded =
167
Full text articles assessed
for eligibility = 1
Studies included in
analysis = 1
Third search (March 2018):
Records identified through 
database searching = 706
Records after duplicates removed = 642
Titles and abstracts
screened = 642
Records excluded =
627
Full text articles assessed
for eligibility = 15
Studies included in
analysis = 4
Full text articles
excluded = 11
with reasons;
long term care
facility (n 1),
pilot study (n 3),
not MCI (n 4),
not RCT design
(n 2), no clear
diagnosis of MCI
(n 1)
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. MCI, mild cognitive impairment.
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Table 2. Overview of study characteristics
Author, year
and location
MCI sample
characteristics
Diagnostic criteria
for MCI Intervention
Study
duration Outcome measures
Bayer-Carter et al.
(2011)(38) (n 49)
USA
68·4 years
aMCI=29
High=15
Low=14
Healthy controls=20
High=9
Low=11
Lost to follow up=no detail
Petersen (2004)(82) Intervention groups:
(1) High diet – 45% fat (saturated fat 25%),
35–40% carbohydrate (GI >70) and 15–20%
protein
(2) Low diet – 25% fat (saturated fat <7%),
55–60% carbohydrate (GI <55) and 15–20%
protein
Control group: healthy adult control group
4 weeks Immediate and delayed memory: story recall, word
list, brief visuospatial memory test; executive
function: trail making test part B, Stroop test,
verbal fluency test;
motor speed: trail making test part A, Stroop test;
AD biomarkers
CSF Aβ42, CSF Aβ40, tau protein
phosphorylated tau, ApoE
Horie et al. (2016)
(n 80)(37) Brazil
68·1 years
Intervention=40
Control=40
Lost to follow up=5
European
Consortium on
Alzheimer’s
Disease(80)
Intervention group: energetic restriction and
counselling with nutritionists (26–28×1 h
meetings). Advice-eating a diet rich in fibre,
fruits, vegetables, wholegrains and included at
least 1 g/kg body weight of protein/d.
Recommended energy deficit of approximately
500 kcal/d (2092 kJ/d) (min 1200 kcal/d (5021 kJ/d))
Control group: conventional medical care with
consultant geriatrician
All participants were advised to engage in physical
activity (at least 150min/week of moderate intensity
aerobic activity or walking)(35)
12 months Verbal memory: RAVLT delayed recall, total
learning and recall recognition; attention: digit
span forward, digit span backward, trail making
test part A; working memory: digit span
backwards, trail making test part; psychomotor
processing speed: trail making test part A, trail
making test part B; executive function: modified
Wisconsin Card Sorting Test, trail making test
part B, verbal fluency; language: phonemic
verbal fluency, semantic verbal fluency
Krikorian et al.
(2012)(12) (n 23)
USA
70·1 years
High carbohydrate=11
Low carbohydrate=12
Lost to follow up=0
CDR(81) Intervention groups: high carbohydrate (50% of
total energy content) v. a very low carbohydrate
group (5–10% total energy content). Intake of
protein and fat were allowed to vary and total
energy intake was not restricted
6 weeks Working memory and executive ability: trail making
test, part B. Secondary or long term memory: V-
PAL test
de Jager et al.
(2012)(25) (n 266)
UK
76·8 years
Intervention=133
Control=133
Lost to follow up=43
Petersen criteria
(2004)(82)
Intervention group: 0·8mg folic acid, 0·5mg vitamin
B12, 20 mg vitamin B6 (daily)
Control group: vitamin-free tablets of similar
appearance
2 years Global cognition: MMSE; episodic memory: HVLT-
R; semantic memory: category fluency CERAD;
executive function: CLOX; clinical outcome
measures: CDR
Ma et al. (2016)(24)
(n 180) China
65 years
Intervention=90
Control=90
Lost to follow up=21
Petersen criteria
(2004)(82)
Intervention group: oral folic acid (400 μg/d).
Participants were instructed to supplement with
one tablet daily, during or immediately after a
meal
Control group: conventional medical treatment
6 months Chinese version of the WAIS-RC-information,
similarities, vocabulary, comprehension,
arithmetic, digit span, block design, picture
completion, digit symbol-coding, object assembly
and picture arrangement
DeKosky et al.
(2008)(26) (total
study n 3069, n
482 with MCI) USA
79·1 years
Intervention=256
Control=226
Lost to follow up: 195 (total
study)
International Working
Group on MCI
Guidelines(83)
Intervention group: twice-daily doses of 120mg
G. biloba extract
Control group: received an identically appearing
placebo
6·1 years Diagnosis of dementia by DSM-IV criteria, modified
MMSE, CDR, ADAS-Cog
Lee et al. (2013) (n
36)(27) Malaysia
65·0 years
Intervention=18
Control=18
Lost to follow up=1
Petersen criteria
(2004)(82)
Intervention group: 3×1-g soft gelatine capsules
each day, each containing 430mg of DHA and
150mg of EPA
Control group: isoenergetic placebo maize oil (0·6 g
linoleic acid)
12 months Memory: visual reproduction I and II, RAVLT, digit
span backward; executive function and attention:
clock drawing test, digit span forward;
psychomotor speed: digit symbol substitution
test; visuospatial skills: matrix reasoning, block
design; global cognitive function: MMSE
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Table 2. Continued
Author, year
and location
MCI sample
characteristics
Diagnostic criteria
for MCI Intervention
Study
duration Outcome measures
Petersen et al.
(2005)(31) (total
study n 769) USA
and Canada
72·9 years
Donepezil=253
Vitamin E=257
Placebo=259
Lost to follow up: 230 (total
study)
Petersen (1999)(84) Intervention group:
(1) 2000 IU (1·3mg) of vitamin E, placebo
donepezil and a multivitamin daily; (2) 10 mg of
donepezil, placebo vitamin E and a multivitamin
daily. The multivitamin contained 15 IU of vitamin
E. The initial dose of vitamin E was 1000 IU daily,
and the dose was increased to 2000 IU (1000 IU
twice daily) after 6 weeks
Control group: received a placebo vitamin E,
placebo donepezil and a multivitamin daily
3 years Primary end-point: time to development of possible
of probable Alzheimer’s disease; secondary:
MMSE, ADAS-Cog, global CDR,
CDR-SB, the global deterioration scale
neuropsychological battery consisting of: New
York University paragraph recall test, symbol
digit modalities test, category fluency test,
number-cancellation test, Boston naming test,
digits-backwards test, clock drawing test, maze
tracing task
Desideri et al.
(2012)(34) (n 90)
Italy
71·2 years
High=30
Medium=30
Low=30
Lost to follow up: 3
(included in analysis)
Petersen criteria
(2004)(82)
Intervention group: once daily a dairy-based cocoa
drink containing cocoa flavanols either at – (1)
high flavanol (990mg of flavanols per serving),
(2) intermediate flavanol (520 mg of flavanols per
serving) and (3) low flavanol (45 mg of flavanols
per serving)
8 weeks MMSE, trail making test A and B, verbal fluency
test
Krikorian et al.
(2010)(35) (n 12)
USA
72·8 years
Male and female
Intervention=5
Control=7
Lost to follow up=0
CDR(81) Intervention group: 100% concord grape juice. A
dosing schedule was instituted determined by
body weight to maintain daily consumption
between 6 and 9ml/kg, a range consistent with
other human grape juice trials. Taken daily in
equal, divided dosages with the morning, midday
and evening meals
Control: contained no juice or natural polyphenol
12 weeks Memory: CVLT, spatial paired associate
learning test
Krikorian et al.
(2010)(36) (n 9)
USA
76·2 years
Male and female
Intervention=no detail
Control=no detail
Lost to follow up=no detail
CDR(81) Intervention group: wild blueberry juice prepared
from ripe, frozen wild (lowbush) blueberries.
Taken daily in equal divided dosages with
morning, mid-day and evening meals. Daily
consumption was maintained between 6 and 9
ml/kg by using a dosing schedule determined by
body weight
Control: contained no juice or natural polyphenol
12 weeks Memory: V-PAL test and CVLT
Krikorian et al.
(2010)(32) (n 26)
USA
71·0 years
Intervention=15
Control=11
Lost to follow up=no detail
CDR(81) Intervention group: chromium picolinate containing
1000 μg elemental Cr
Control group: placebo – no details
12 weeks Memory: CVLT
functional MRI scanning
Bo et al. (2017) (n
86)(28) China
71·1 years
Intervention=42
Control=44
Lost to follow up=22
Petersen criteria
(1999)(84)
Intervention group: 625mg DHA+600mg EPA
(twice daily)
Control group: placebo capsules containing olive oil
(twice daily)
6 months Basic cognitive aptitude tests: digit copy, Chinese
character comparison, mental arithmetic,
Chinese character rotation, recall answer of
mental arithmetic, recognition of two‐word
nouns, and recognition of meaningless figures.
These seven sub‐items were divided into five
sections: perceptual speed, mental arithmetic
efficiency, space imagery efficiency, working
memory and recognition memory
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Table 2. Continued
Author, year
and location
MCI sample
characteristics
Diagnostic criteria
for MCI Intervention
Study
duration Outcome measures
Soininen et al.
(2017)(33) (n 311)
Finland
71·0 years
Intervention=153
Control=158
Lost to follow up/
discontinued=66
Dubois et al.
(2007)(85)
Intervention group: medical food Souvenaid, a 125
ml once-a-day drink containing the specific
nutrient combination Fortasyn Connect (1200mg
DHA, 300mg EPA, 106mg phospholipids, 400
mg choline, 625mg UMP, 40mg vitamin E, 80
mg vitamin C, 60 μg Se, 3 μg vitamin B12, 1 mg
vitamin B6, 400 μg folic acid)
Control group: 125ml once-a-day control drink
24 months Primary end points: composite Z score based on
CERAD ten-word list learning immediate recall,
CERAD ten-word delayed recall, CERAD ten-
word recognition, category fluency and LDST.
Memory (CERAD ten-word list learning
immediate recall, delayed recall and recognition);
executive function (category fluency, Wechsler
Memory Scale revised digit span total score,
concept shifting test condition C (corrected for
the zero trials) and LDST); NTB total (composite
Z score based on all sixteen items of the NTB);
secondary end points: CDR-SB; brain volumes
based on MRI; progression to dementia by DSM-
IV Criteria
Zhang et al. (2017) (n
240)(30) China
74·5 years
Intervention=120
Control=120
Lost to follow up=21
Petersen criteria
(2004)(82)
Intervention group: DHA supplementation (2 g/d)
Control group: maize oil
12 months Chinese version of the WAIS-RC. The WAIS-RC
includes eleven sub-tests: information,
similarities, vocabulary, comprehension,
arithmetic, digit span, block design, picture
completion, digit symbol-coding, object assembly
and picture arrangement
Phillips et al.
(2015)(29) (n 57)
UK
68·7 years
Intervention=29
Control=28
Lost to follow up=2
Petersen criteria
(2004)(82)
Intervention group: 625mg DHA+600mg EPA
(twice daily)
Control group: placebo capsules containing olive oil
(twice daily)
4 months MMSE; Hopkins Learning Test Revised and
neuropsychological measures of executive
functioning, language, verbal reasoning and
visual memory
MCI, mild cognitive impairment; aMCI, amnesic mild cognitive impairment; GI, glycaemic index; AD, Alzheimer’s disease; RAVLT, Rey Auditory Verbal Learning Test; CDR, clinical dementia rating; V-PAL, verbal paired associates learning;
MMSE, Mini Mental State Examination; HVLT-R, Hopkins Verbal Learning Test – revised; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; CLOX, executive clock drawing task; WAIS-RC, Wechsler Adult Intelligence
Scale Revised; ADAS-Cog, Alzheimer’s Disease Assessment Scale cognitive assessment; CDR-SB, clinical dementia rating-sum of boxes; CVLT, California Verbal Learning Test; LDST, letter digit substitution test; NTB,
neuropsychological test battery.
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displayed according to the primary (incident dementia or AD)
and secondary (cognitive function) outcomes. For cognitive
function, as per the NIA-AA criteria for the diagnosis of MCI(3),
the results were grouped according to the following cognitive
domains: (1) memory; (2) executive function; (3) attention;
(4) language and (5) visuospatial skills, with an additional
section reporting global cognitive function. When papers did
not specify the cognitive domain measured, the results were
grouped under ‘additional cognitive function measures’ (online
Supplementary Table S2). A descriptive list of the most
frequently reported cognitive function tests used in the studies
is provided in the online Supplementary material.
Study characteristics
An overview of the study characteristics is shown in Table 2. Of the
sixteen studies included in analysis, thirteen studies used dietary
supplements or single foods as their diet intervention, including
folic acid(24), vitamin B combination (folic acid, vitamin B12 and
vitamin B6)
(25), Gingko biloba(26), n-3 fatty acids (DHA+EPA(27–29)
and DHA(30)), vitamin E(31), Cr supplementation(32), the medical
food, Souvenaid containing the specific nutrition combination
Fortasyn Connect(33), cocoa flavanols(34), concord grape juice(35)
and wild blueberry juice(36). The three remaining studies focused
their interventions on nutritional counselling in combination with
healthy eating advice and energy restriction(37), high-saturated fat/
high-glycaemic index (GI) diet v. a low-saturated fat/low-GI diet(38)
and a high carbohydrate v. a very low carbohydrate diet(12). A
figure detailing the included studies and their dietary exposure
linked to the cognitive outcome measures assessed is provided
in the online Supplementary material (Fig. 1). One study(37)
encouraged both intervention and control participants to partake
in physical activity (150min/week) as per World Health
Organization(39) recommendations. There were no studies which
included cognitive strategies as part of their intervention.
Furthermore, two studies stated that participants had amnesic
mild cognitive impairment (aMCI)(38) or prodromal AD(33) while all
other studies reported a diagnosis of MCI.
Primary outcome measure – incident dementia and
Alzheimer’s disease
In all, three of the included studies had an outcome measure of
incident dementia and/or AD(26,31,33). Vitamin E supplementation
over 3 years showed no significant difference in the diagnostic
rate of AD in participants with MCI taking vitamin E (2000 IU) v.
placebo (hazard ratio (HR) 1·02, 95% CI 0·57, 1·13)(31). In the
vitamin E group, 33/257 (13%) and 38/259 (15%) participants in
the placebo group progressed to possible or probable AD in the
first 12 months (relative risk (RR) 1·02, 95% CI 0·96, 1·10). At
36 months, 76/257 (30%) in the vitamin E group and 73/259
(28%) in the placebo had progressed to AD (RR 1·03, 95% CI
0·79, 1·35)(31). Likewise, a USA based study with intervention
follow up over 6·1 years and found no significant difference
between G. biloba v. placebo for the outcomes of all dementia
(9·82/100 person-years v. 8·68/100 person-years, HR 1·13, 95%
CI 0·85, 1·50), AD without vascular dementia (VaD) (7·02/100
person-years v. 6·09/100 person-years, HR 1·15, 95% CI 0·83,
1·61), AD with VaD (2·10/100 person-years v. 2·20/100 person
years, HR 0·96, 95% CI 0·54, 1·71), total AD (9·12/100 person-
years v. 8·28/100 person-years, HR 1·10, 95% CI 0·83, 1·47) and
VaD without AD (0·18/100 person-years v. 0·30/100 person-
years, HR 0·59, 95% CI 0·10, 3·51)(26). Finally, supplementation
with Souvenaid (125ml/d of the specific nutrition combination
Fortasyn Connect) v. control, showed no statistically significant
difference in diagnosis of dementia at 24 months between groups
(59/158 (37%) (control) v. 62/153 (41%) (intervention))(33).
Secondary outcome measure-cognitive function
Memory. As shown in Table 3, there were twenty-five cogni-
tive tests used to measure the domain of memory, and it was
assessed in fifteen out of the sixteen studies (94%) and hence
was the most tested cognitive domain. Overall, nine out of the
fifteen studies (53%) (B vitamin(25), DHA+EPA(27–29), DHA(30),
vitamin E(31), cocoa flavonols(34), concord grape juice(35) and
wild blueberry juice(36)) showed a significant difference
between groups at study completion in at least one cognitive
function test measuring memory. Fish oil supplementation
(3× 430mg DHA+ 150mg EPA daily for 12 months), produced
significant improvements in visual reproduction I and Rey
Auditory Verbal Learning Test delayed recall v. placebo group
(all P< 0·05)(27). In addition, there was a significant
improvement in memory performance (cognitive Z score) in
the fish oil v. placebo group (P= 0·001)(27). In a second study
investigating n-3 PUFA supplementation (480mg DHA+ 720mg
EPA daily for 6 months v. placebo)(28), borderline statistical
significance (P= 0·047) was reported between intervention and
control for working memory. However, a third study
investigating 625mg EPA+ 600mg DHA v. placebo showed
no significant improvements in memory(29). A fourth study who
investigated DHA supplementation only (2mg/d v. placebo)(30),
found significant improvements for short-term memory
(P≤ 0·0001) and long-term memory (P≤ 0·0001) in
comparison to the placebo group. In a trial investigating the
effect of cocoa flavanols (high flavonols (HF) 990mg v.
intermediate flavonols (IF) 520mg v. low flavonols (LF) 45mg
of flavanols daily for 8 weeks)(34), verbal fluency test scores
significantly improved (P= 0·0001), with a significantly greater
score in HF participants in comparison with the LF group
(P≤ 0·05).
B vitamin supplementation(25) (0·8mg folic acid, 0·5mg
vitamin B12, 20mg vitamin B6 daily for 2 years), demonstrated
improvement in verbal memory but only in those participants
with low baseline B vitamin/folic acid status. The odds of
correctly remembering a word in the Hopkins Verbal Learning
Test were 69% greater for a person in the high total
homocysteine (tHcy) group if they were taking B vitamins,
than if they were taking placebo (OR= 1·69, P= 0·001)(25). For
category fluency (Consortium to Establish a Registry for
Alzheimer’s Disease), in the high tHcy group, the average
number of words was 9·4% greater at follow up in those on B
vitamin treatment compared with the placebo (P= 0·04).
However, in the low tHcy group (indicating higher B vitamin/
folic acid status) there was no significant difference between the
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Table 3. Summary table of cognitive function results grouped as per National Institute for Aging-Alzheimer’s Association (NIA-AA)(3) criteria
NIA-AA cognitive
domain Study Intervention Cognitive function measure used Intervention group and control group results
Between group
difference
Memory Horie et al., 2016(37) Nutrition counselling and energy
restriction v. standard care
RAVLT (delayed recall) Intervention (mean change 0·7, 95% CI –0·9, 2·3); control
(mean change 1·7, 95% CI 0·1, 3·3)
‡
RAVLT (total learning) Intervention (mean change 3·3, 95% CI –1·3, 7·9); control
(mean change 2·0, 95% CI –2·6, 6·7)
‡
Digit span backward Intervention (0·2, 95% CI –0·8, 1·2); control (0·1, 95% CI –0·9, 1·1) ‡
Trail making test, part B Intervention (mean change –8·6, 95% CI −71·6, 54·5); control
(mean change 5·1, 95% CI –58·3, 68·6)
‡
Lee et al. (2013)(27) Fish oil supplementation with
concentrated DHA+EPA v.
placebo
RAVLT (delayed recall) Intervention (baseline mean score 6·7, 95% CI 4·897, 8·442 –
12 months mean score 8·1, 95% CI 6·645, 9·462); control
(baseline mean score 6·1, 95% CI 4·431, 7·860 – 12 months
mean score 5·0, 95% CI 3·587, 6·312)
*
Visual reproduction I Intervention (baseline mean score 20·0, 95% CI 15·234, 24·820 –
12 months mean score 29·2, 95% CI 25·207, 33·269); control
(baseline mean score 21·0, 95% CI 16·394, 25·666 – 12 months
mean score 23·1, 95% CI 19·154, 26·952)
*
Visual reproduction II Intervention (baseline mean score 13·3, 95% CI 8·297, 18·362 –
12 months mean score 20·8, 95% CI 15·564, 26·110); control
(baseline mean score 12·6, 95% CI 7·710, 17·445 – 12 months
mean score 18·0, 95% CI 12·943, 23·143)
‡
Digit symbol substitution Intervention (baseline mean score 5·5, 95% CI 3·723, 7·218 –
12 months mean score 5·5, 95% CI 3·723, 7·218); control
(baseline mean score 4·9, 95% CI 3·254, 6·634 – 12 months 4·9,
95% CI 3·254, 6·634)
‡
Memory cognitive Z-score Intervention (mean change 0·96 (SD 0·76)***); control (mean change
0·16, (SD 0·59))
*
Petersen et al.
(2005)(31)
2000 IU vitamin E, 10mg
donepezil or placebo
Memory Z score (ADAS recall scores
and New York University recall
scores)
Intervention (6 months, Z score –0·10, SD 0·48; 36 months Z score –
0·31, SD 0·59); control (6 months, Z score –0·17, SD 0·47;
36 months Z score –0·28, SD 0·62)
‡
Ma et al. (2016)(24) Oral folic acid (400 μg/d) v.
conventional treatment
Digit span Intervention (baseline mean score 9·27 (SD 3·11) – 6 months mean
score 13·05 (SD 3·07); control (baseline mean score 8·87
(SD 2·70) – 6 months mean score 9·75 (SD 3·14)
*
De Jager et al.
(2012)(25)
0·8mg folic acid, 0·5mg vitamin
B12 and 20mg vitamin B6 v.
placebo
HVLT-R (subgroup analyses,
with baseline tHcy levels)
The odds of correctly remembering a word from the list of twelve in
the HVLT test were 69% greater for a person in the high tHcy
group if they were taking B vitamins than if they were taking
placebo (OR=1·69)
*
CERAD (subgroup analyses,
with baseline tHcy levels)
The average number of words was 9·4% greater at follow up in
those on B vitamin treatment in the high tHcy group, compared
with the placebo (OR= 0·09)
*
Bayer-Carter et al.
(2011)(38)
High fat/high GI diet v.
low fat/low GI diet
Brief visuospatial memory test aMCI low diet baseline mean score 7·39 (SEM 0·71) – week 4 mean
score 8·31 (SEM 0·62); aMCI high diet baseline mean score 8·27
(SEM 0·66) – week 4 mean score 8·40 (SEM 0·58); healthy controls
high diet baseline mean score 9·89 (SEM 0·85) – week 4 mean
score 9·56 (SEM 0·74); healthy controls low diet baseline mean
score of 8·27
(SEM 0·77) – week 4 mean score 9·82 (SEM 0·67)
‡
Story recall aMCI low diet baseline mean score 18·48 (SEM 1·43) – week 4 mean
score 21·46 (SEM 1·70); aMCI high diet baseline mean score 20·37
(SEM 1·31) – week 4 mean score 22·30 (SEM 1·59); healthy controls
high diet baseline mean score 22·69 (SEM 1·7 4) – week 4 mean
score 23 19 (SEM 2·04); healthy controls low diet baseline mean
score 21·09 (SEM 1·55) – week 4 mean score 19·90 (SEM 1·95)
‡
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Table 3. Continued
NIA-AA cognitive
domain Study Intervention Cognitive function measure used Intervention group and control group results
Between group
difference
Word list aMCI low diet baseline mean score 11·62 (SEM 0·76) – week 4 mean
score 11·77 (SEM 0·80), aMCI high diet baseline mean score 11·33
(SEM 0·71); healthy controls low diet baseline mean score 13·27
(SEM 0·93) – week 4 mean score 13·27 (SEM 0·96), healthy controls
high diet baseline mean score 12·79 (SEM 0·92) – week 4 mean
score 13·67 (SEM 0·95)
–
Krikorian et al.
(2012)(12)
High carbohydrate v. a very low
carbohydrate
Trail making test, part B Intervention (pre-intervention mean score 79·2 s v. post intervention
mean score 82·9 s, F1,20=0·46, P= 0·50); control (no detail)
–
V-PAL Intervention (pre-intervention mean score 11·8 s v. post intervention
mean score 14·6 s, F1,20=6·45, P= 0·01); control (no detail)
‡
Krikorian et al.
(2010)(35)
Concord grape juice
supplementation v. placebo
CVLT learning Intervention mean change 3·4; control mean change 0·0; ANCOVA
analysis intervention v. control F1,8=5·55, P= 0·04, Cohen’s
f= 0·28
*
CVLT recall Intervention mean change 1·2; control mean change –0·4; ANCOVA
analysis intervention v. control P=0·10; Cohen’s f=0·35
‡
Spatial paired associate learning
task
Intervention mean change 1·7; control mean change −0·4; ANCOVA
analysis intervention v. control P=0·12; Cohen’s f=0·67
‡
Krikorian et al.
(2010)(36)
Wild blueberry juice
supplementation v. placebo
V-PAL Intervention (baseline mean score 9·3 v. week 12 mean score
13·2†); control (no detail); ANCOVA analysis intervention v.
control F1,13=5·58
*
CVLT Intervention (baseline mean score 7·2 v. week 12 mean score 9·6†);
control (no detail); ANCOVA analysis intervention v. control
F1,13=2·27
‡
Krikorian et al.
(2010)(32)
Chromium picolinate
supplementation v. placebo
CVLT learning Intervention v. control mean score at 12 weeks (46·8 v. 45·8) ‡
Intrusion errors intervention v. control at 12 weeks (0·20 v. 1·27);
F1,23=6·48; Cohen’s f=0·51
*
CVLT delay recall Intervention v. control mean score at 12 weeks (9·4 v. 8·4) ‡
Intrusion errors intervention v. control at 12 weeks (0·98 v. 2·3),
F1,23=3·35, Cohen’s f=0·35
‡
CVLT long delay recall Intervention v. Control mean score at 12 weeks (9·3 v. 9·5) ‡
Intrusion errors intervention v. control at 12 weeks (0·98 v. 2·3),
F1,23=3·35, Cohen’s f=0·35
‡
CVLT recognition memory Intervention v. control mean score at 12 weeks (14·4 v. 14·2) ‡
Intrusion errors intervention v. control at 12 weeks (0·88 v. 2·2),
F1,23=2·94, Cohen’s f=0·34
‡
Desideri et al.
(2012)(34)
990mg HF v. IF v. LF cocoa
flavanols per day
Verbal fluency HF (mean change 8·0 (SD 5·3) words per 60 s***); IF (mean change
5·1 (SD 3·1) words per 60 s***), LF (mean change 1·2 (SD 2·7)
words per 60 s†)
*
Bo et al. (2017)(28) 480mg of DHA+720mg of EPA
daily v. placebo
Working memory Intervention mean difference 3·32 (SD 3·45); control mean difference
1·38 (SD 2·66)
*
Recognition memory Intervention: mean change 1·55 (SD 3·96); control mean change
1·98 (SD 3·13)
‡
Soininen et al.
(2017)(33)
Souvenaid, a 125ml once-a-day
drink v. control
NTB memory Z score Intervention mean change at 24 months, 0·003 (SD 0·569); control
mean change at 24 months –0·130 (SD 0·619)
‡
Zhang et al.
(2017)(30)
2 g/d DHA v. placebo Information test Intervention mean score 12·28 (SD 3·56); control mean score 10·82 (SD
2·62)
*
Digit span Intervention mean score 13·44 (SD 3·66); control mean score 10·25 (SD
3·42)
*
Phillips et al.
(2015)(29)
625mg EPA+600mg DHA v.
placebo
Immediate verbal memory Intervention mean score (month 1, 19·42 (SD 3·49) – month 4, 17·46
(SD 4·52)); control mean score (month 1, 20·50 (SD 4·31) – month
4, 19·38 (SD 4·65))
–
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Table 3. Continued
NIA-AA cognitive
domain Study Intervention Cognitive function measure used Intervention group and control group results
Between group
difference
Delayed verbal memory Intervention mean score (month 1, 4·85 (SD 2·91) – month 4, 4·34
(SD 2·74)); control mean score (month 1, 5·23 (SD 2·63) – month 4,
4·65 (SD 2·79))
‡
Recognition verbal memory Intervention mean score (month 1, 8·92 (SD 2·06) – month 4, 8·38
(SD 2·30)); control mean score (month 1, 9·00 (SD 2·80) – month 4,
8·00 (SD 2·55))
–
Visual memory Intervention mean score (month 1, 11·58 (SD 2·19) – month 4, 12·77
(SD 2·67); control mean score (month 1, 11·50 (SD 2·60) – month 4,
11·85 (SD 1·95))
‡
Executive
function
Lee et al. (2013)(27) Fish oil supplementation with
concentrated DHA+EPA v.
placebo
Digit symbol substitution Intervention (baseline mean score 5·5, 95% CI 3·723, 7·218 –
12 months mean score 5·5, 95% CI 3·723, 7·218); control
(baseline mean score 4·9, 95% CI 3·254, 6·634 – 12 months
mean score 4·9, 95% CI 3·254, 6·634)
–
CDT Intervention (baseline mean score 7·3, 95% CI 6·810, 7·880 –
12 months mean score 7·8, 95% CI 7·142, 8·477); control
(baseline mean score 7·5, 95% CI 6·935, 7·969 – 12 months
mean score 7·8, 95% CI 7·145, 8·436)
‡
Executive function Z score
(cumulative score of all tests used)
Intervention (mean change 0·52 (SD 0·869)†); control (mean change
−0·238 (0·683))
‡
Petersen et al.
(2005)(31)
2000 IU vitamin E, 10mg
donepezil or placebo
Executive function Z score (digits
backwards test, symbol digit
modalities test and number –
cancellation test)
Intervention (6 months Z score 0·11, SD 0·41§ – 36 months Z score –
0·19, SD 0·48); control (6 months Z score 0·04, SD 0·42 –
36 months Z score –0·19, SD 0·53)
‡
Horie et al.
(2016)(37)
Nutrition counselling and energy
restriction v. standard care
Trail making test, part B Intervention (mean change –8·6, 95% CI –71·6, 54·5); control
(mean change 5·1, 95% CI –58·3, 68·6)
‡
Phonemic fluency Intervention (mean change 0·1, 95% CI –0·5, 5·1); control
(mean change 2·0, 95% CI –3·1, 7·1)
‡
Semantic fluency Intervention (mean change 1·1, 95% CI –1·4, 3·6); control
(mean change 1·9, 95% CI –0·6, 4·4)
‡
Modified Wisconsin Card Sorting
Test
Intervention (mean change 0·4, 95% CI –0·3, 1·0); control
(mean change 0·7, 95% CI –0·1, 1·4)
‡
Krikorian et al.
(2012)(12)
High carbohydrate diet v. very low
carbohydrate
Trail making test, part B Intervention (pre-intervention mean score 79·2 s v. post intervention
mean score 82·9 s, F1,20=0·46); control (no detail)
‡
Bayer-Carter et al.
(2011)(38)
High fat/high GI diet v. low fat/low
GI diet
Trail making test, part B The authors did not include these data in their published paper,
merely stating no diet related changes in the text
‡
Stroop colour word
test
Verbal fluency
De Jager et al.
(2012)(25)
0·8mg folic acid, 0·5mg vitamin
B12 and 20mg vitamin B6 v.
placebo
CLOX (subgroup analyses, with
baseline tHcy levels)
The odds of a correctly drawn item from CLOX1, after controlling for
confounders (CLOX2 at follow-up, CLOX1 at baseline, age,
education, ApoE ε4 status and sex), was 30% greater in those
receiving B-vitamins in comparison to placebo (OR=0·26)
*
Desideri et al.
(2012)(34)
990mg HF v. IF v. LF cocoa
flavanols per day
Trail making test, part B HF (mean change –29·2 (SD 8·0) s***), IF (mean change –22·8
(SD 5·1) s***) LF (mean change 3·8 (SD 16·3) s)
*
Soininen et al.
(2017)(33)
Souvenaid, a 125ml once-a-day
drink v. control
NTB executive function Z score Intervention mean change at 24 months –0·145 (SD 0·445); control
mean change at 24 months –0·039 (SD 0·506)
‡
Phillips et al.
(2015)(29)
625mg EPA+600mg DHA v.
placebo
CLOX2 Intervention mean score (month 1, 14·08 (SD 0·89) – month 4, 14·08
(SD 14·08)); control mean score (month 1, 14·38 (SD 0·75) – month
4, 14·27 (SD 0·67))
‡
Attention Horie et al.
(2016)(37)
Nutrition counselling and energy
restriction v. standard care
Digit span forward Intervention (mean change −0·4, 95% CI –1·1, 0·3); control
(mean change 0·1, 95% CI –0·6, 0·9)
‡
Digit span backward Intervention (mean change 0·2, 95% CI –0·8, 1·2); control
(mean change 0·1, 95% CI –0·9, 1·1)
‡
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Table 3. Continued
NIA-AA cognitive
domain Study Intervention Cognitive function measure used Intervention group and control group results
Between group
difference
Trail making test, part A Intervention (mean change –6·1 95% CI –22·6, 10·4); control
(mean change –0·7, 95% CI –17·3, 15·9)
‡
Lee et al. (2013)(27) Fish oil supplementation with
concentrated DHA+EPA v.
placebo
CDT Intervention (baseline mean score 7·3, 95% CI 6·810, 7·880 –
12 months mean score 7·8, 95% CI 7·142, 8·477); control
(baseline mean score 7·5, 95% CI 6·935, 7·969 – 12 months
mean score 7·8, 95% CI 7·145, 8·436)
‡
Digit span forward test Intervention (baseline mean score 8·0, 95% CI 6·99, 9·04 –
12 months mean score 9·6, 95% CI 8·437, 10·749); control
(baseline mean score 8·5, 95% CI 7·554, 9·529 – 12 months
mean score 8·0,
95% CI 6·877, 9·113)
*
Attention Z score Intervention (mean change 0·52 (SD 0·869)†); control (mean change
–0·238 (0·683))
‡
Desideri et al.
(2012)(34)
990mg HF v. IF v. LF cocoa
flavanols per day
Trail making test, part A HF (mean change –14·3 (SD 4·2) s***), IF (mean change –8·8 (SD
3·4) s***), LF (mean change 1·1 (SD 13·0) s)
*
Zhang et al.
(2017)(30)
2 g/d DHA v. placebo Digit span Intervention mean score 13·44 (SD 3·66); control mean score 10·25
(SD 3·42)
*
Philips et al.
(2015)(29)
625mg EPA+600mg DHA v.
placebo
Basic attention Intervention mean score (month 1, 6·38 (SD 1·47) – month 4, 6·54
(SD 1·33); control mean score (month 1, 6·65 (1·36) – month 4,
6·77 (SD 1·31))
‡
Language Horie et al.
(2016)(37)
Nutrition counselling and energy
restriction v. standard care
Semantic fluency Intervention (mean change 1·1, 95% CI –1·4, 3·6); control (mean
change 1·9, 95% CI –0·6, 4·4)
‡
Phonemic fluency Intervention (mean change 0·1, 95% CI –0·5, 5·1); control (mean
change 2·0, 95% CI –3·1, 7·1)
‡
Petersen et al.
(2005)(31)
2000 IU vitamin E, 10mg
donepezil or placebo
Language Z score (Boston naming
test and category fluency test)
Intervention (6 months Z score 0·07, SD 0·23§ – 36 months Z score –
0·10, SD 0·35); control (6 months Z score 0·03, SD 0·23 –
36 months –0·08, SD 0·33)
‡
VS Lee et al. (2013)(27) Fish oil supplementation with
concentrated DHA+EPA v.
placebo
Matrix reasoning block design test Intervention (baseline mean score 7·6, 95% CI 6·37, 8·75 –
12 months mean score 7·1, 95% CI 6·27, 7·96); control (baseline
mean score 7·3, 95% CI 6·16, 8·45 – 12 months mean score 7·9,
95% CI 7·07, 8·71)
‡
VS Z score Intervention (mean change 0·17 (SD 0·84)); control (mean change
0·04 (SD 0·60))
‡
Petersen et al.
(2005)(31)
2000 IU vitamin E, 10mg
donepezil or placebo
VS Z score (CDT) Intervention (6 month Z score 0·03, SD 0·34 – 36 months Z score –
0·12, SD 0·37); control (6 month Z score –0·01, SD 0·34 –
36 months Z score –0·11, SD 0·39)
‡
Ma et al. (2016)(24) Folic acid (400 μg/d) v. control Block design test Intervention (baseline mean score 9·77 (SD 5·41) – 6 months mean
score 13·28 (SD 4·21)); control (baseline mean score 9·93 (SD
2·273) – 6 months mean score 11·33 (SD 3·11))
*
Zhang et al.
(2017)(30)
2mg DHA v. placebo Block design test Intervention (baseline mean score 10·25 (SD 5·30 – 12 months mean
score 11·19 (SD 4·07); control (baseline mean score 9·63 (SD 2·46)
– 12 months mean score 10·43 (SD 3·51))
‡
RAVLT, Rey Auditory Verbal Learning Test; HVLT-R, Hopkins Verbal Learning Test – Revised; tHcy, total homocysteine; GI, glycaemic index; aMCI, amnesic mild cognitive impairment; V-PAL, Verbal Paired Associates Learning; CVLT,
California Verbal Learning Test; CDT, clock drawing test; NTB, neuropsychological test battery; CLOX, executive clock drawing task.
* Statistically significant difference (P≤0·05) between intervention and control groups at study completion.
† Statistically significant difference P≤0·05 within group.
‡ No statistically significant difference between intervention and control at study completion.
§ Statistically significant difference between intervention and control at stated time-point.
*** Statistically significant difference P≤ 0·001 within group.
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treatment group and placebo(25). In another B vitamin study,
investigating folic acid alone (400 μg daily for 6 months) v.
conventional treatment(24) results showed for short term
memory that the intervention group had a significant increase
in score from baseline to 6 months in comparison to the control
(P≤ 0·001). Results also indicated that elevated homocysteine
levels at baseline were associated with significantly poorer
cognitive performance at intervention completion for the
intervention group in comparison to the control(24).
Vitamin E supplementation (2000 IU daily for 2 years)(31), the
medical food, Souvenaid containing the specific nutrition
combination Fortasyn Connect (125ml daily)(33) and chromium
picolinate (CrPic) supplementation (1000 μg daily for
12 weeks)(32) had no significant improvement in comparison to
placebo for memory. Supplementation with CrPic showed
significantly reduced intrusion errors, with the intervention
group making significantly fewer errors on California Verbal
Learning Test (CVLT) for learning (P= 0·01) than the placebo
group, however there was no significant reduction for recall and
recognition memory(32). In an investigation of the effects of a
high carbohydrate diet (50% of total energy content) v. a very
low carbohydrate (5–10% of total energy content) diet in
participants with MCI(12), pre-intervention carbohydrate levels
were recorded as 207 g for those in the ‘high’ carbohydrate group
and 190 g in the ‘low’ carbohydrate group. Post-intervention
carbohydrate levels measured 197 g for the ‘high’ carbohydrate
group and 34 g for the ‘low’ carbohydrate group. These figures
indicate that those in the ‘low’ group had a major dietary change
whereas the ‘high’ group could be regarded as a control. Results
showed no significant effect of the intervention for memory
performance (brief visuospatial memory test, story recall and
word list) between intervention and control groups(12). Concord
grape juice(35) (daily consumption between 6 and 9ml/kg for
12 weeks) significantly improved verbal learning compared with
the placebo (P= 0·04). However, there were no significant
differences between those consuming the grape juice and
placebo for delayed verbal recall and spatial memory(35).
Furthermore, wild blueberry juice(36) (daily consumption
between 6 and 9ml/kg for 12 weeks) had a significant
improvement from baseline score to 12 weeks for verbal
paired associates learning (V-PAL) cumulative learning
(P= 0·009). In addition, mean scores for CVLT word list recall
improved significantly within the intervention group from
baseline to 12 weeks (P= 0·04). There was a significant
difference in V-PAL score between intervention and control
groups (P= 0·03), however no significant difference was
observed for CVLT performance between groups(36).
Executive function. The domain of executive function was
measured by twelve tests (Table 3). For this cognitive domain,
measured within nine studies (56%), two RCT showed a sta-
tistically significant improvement between groups at study
completion(25,34). At 24 months follow-up, the odds of a
correctly drawn item from CLOX1 (an executive clock
drawing task), after controlling for confounders (CLOX2 at
follow-up, CLOX1 at baseline, age, education, ApoE ε4 status
and sex), was 30% greater in those receiving B-vitamins v.
placebo (P= 0·02)(25). For cocoa flavonol supplementation(34),
better scores for trail making test, part B (P≤ 0·05) were
reported among participants who received HF and IF
treatments v. the LF group. In addition, the time required to
complete the trail making task, B significantly changed during
the duration of the study (P≤ 0·0001). However, DHA+EPA
supplementation(27,29), nutritional counselling with energy
restriction(37), high fat/high GI v. low fat/low GI diet(38), high
carbohydrate v. low carbohydrate diet(12), supplementation
with Fortasyn Connect (Souvenaid)(33) and vitamin E(31)
showed no significant difference in cognitive function tests
between groups at study completion. There was a significant
improvement in comparison with placebo at 6 months for those
consuming vitamin E supplements (P< 0·05)(31). However,
thereafter, this significant difference was not maintained
beyond this time point.
Attention. As shown in Table 3, five of the sixteen (31%)
included studies measured the domain of attention. Nutritional
counselling v. standard care showed no significant change in
attention between groups after 12 months(37). Whereas, cocoa
flavonol supplementation(34), significantly better scores for trail
making test, part A (P≤ 0·05) were reported among participants
who received HF and IF treatments in comparison to the LF
group. In addition, the time required to complete the trail
making task, part A significantly changed during the duration of
the study (P≤ 0·0001)(34). DHA+EPA supplementation(27) (one
study) showed a significant improvement in digit span score
from baseline to 12 months in the fish oil group v. placebo
(P≤ 0·0001)(27). However, there was no significant treatment
effect reported between the fish oil and placebo groups for any
of the other measures of attention(27). Supplementation with
DHA only(30) showed significant improvements in digit span
score in comparison to the placebo (P≤ 0·0001). However, a
third study with DHA+EPA supplementation(29) found no
significant differences between groups for attention.
Language. In all, two of the sixteen (13%) studies measured the
cognitive domain of language (Table 3). There were no sig-
nificant differences between groups for nutritional counselling
with energy restriction(37). For vitamin E supplementation(31),
there was a significant difference in score from the baseline
value between groups at 6 months (P≤ 0·05), 12 months
(P≤ 0·05) and 18 months (P≤ 0·05), however, thereafter this
significant difference was not maintained until intervention
completion (36 months)(31).
Visuospatial skills. In all, four studies (25%) measured the
cognitive domain of visuospatial skills (Table 3). Supple-
mentation with folic acid was the only study to show a sig-
nificant interaction effect between groups for visuospatial skills
(P= 0·03)(24). In addition, higher baseline homocysteine levels
were associated with poorer cognitive performance on the
block design test at the end of the intervention in comparison
with the placebo (estimate value= − 0·079, P≤ 0·001)(24). Fish
oil supplementation with concentrated DHA+EPA(27), DHA(30)
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or vitamin E supplementation(31) did not show any significant
differences between groups.
Global cognitive function. For cocoa flavonol supplementa-
tion(34) (online Supplementary Table S2), there was no
significant change in MMSE score between the HF, IF or LF
treatment groups over the duration of the study (P= 0·13).
However, results also showed that the composite cognitive Z
score significantly changed during the study (P≤ 0·0001). The
cognitive Z score at the end of the study follow-up was
significantly (P≤ 0·05) better in the HF group in comparison to
the LF group(34). Vitamin B supplementation(25) indicated no
significant effect of treatment (P= 0·57) on global cognition as
measured by MMSE. However, analysis did show that those
who had high baseline concentrations of homocysteine and
were treated with B vitamins, were 1·58 more likely to provide a
correct answer on the MMSE test than the placebo group
(P< 0·001). However, there was no significant difference for
those with low baseline homocysteine, between the B vitamin
or placebo groups. Similarly, fish oil supplementation(27) (one
study) showed no statistically significant differences between
groups for cognitive function as measured by the MMSE.
Furthermore, vitamin E supplementation(31) at 6 months
intervention showed a significant difference in comparison
with placebo for overall cognitive function calculated by a
composite Z score (P≤ 0·01). However, at 36 months this
significant difference between groups was not maintained.
Assessment of methodological quality and risk of bias
The quality(22) of the sixteen included studies varied, with eight
studies achieving the maximum total score of 5(25–28,30,31,33,34)
(online Supplementary Table S3). Thus, it was deemed that these
studies stated appropriate randomisation processes, were clearly
indicated as double blinded and the authors accounted for any
participant withdrawals during the study. In all, two studies(12,38)
scored one on the Jadad scale(22) and stated that participants
were randomised however did not specify the randomisation
process, if double-blinding took place and if any participant
withdrawals occurred. Low risk of bias scores(23) were allocated
for selection bias (n 9)(24–28,30,31,33,34), performance bias
(n 7)(25,26,28–30,33,34), attrition (n 9)(24,25,27–30,33,34,37) and
detection bias (n 6)(24,26,30,33,34,37) (online Supplementary Table
S4). A high risk score was documented for detection bias (n
3)(12,38) and performance bias (n 2)(12) as there were no details
provided of any double blinding method used.
Discussion
The aim of the present systematic review was to examine the
effect of diet, either alone or in combination with lifestyle and/
or cognitive strategies, on cognitive health outcomes in patients
with MCI. Together with the limited number of RCT conducted
and the heterogeneity of the studies in this review, a narrative
synthesis of the findings was implemented. Studies varied
greatly in terms of the nature of dietary intervention and cog-
nitive outcome measures used. Furthermore, there were no
studies that measured the effectiveness of lifestyle and/or cog-
nitive strategies in combination with their dietary intervention.
Overall, it was evident that the findings were inconsistent across
the studies and do not provide clear evidence to support the
effect of any specific diet or dietary component on cognition in
MCI patients.
Diet has been suggested to have a significant association with
cognitive decline and progression to dementia, particularly
showing a protective role against the harmful effects of neuro-
inflammation and oxidative stress(40). Although the pathways
related to their role are complex and variable throughout the
literature(14–16,41) it is thought that antioxidants in foods such as
fruit and vegetables help to reduce oxidative stress levels in the
brain and n-3 PUFA in foods such as oily fish, are additionally
linked to reduced inflammation(8). There are plausible
suggestions to support these mechanisms by the results of this
review. There were some improvements in cognitive function,
particularly in the domain of memory, reported for polyphenol
compounds (e.g. cocoa flavonols(34)), fish oil supplementation
with concentrated DHA+EPA(27,28) or DHA alone(30) and
beverages which are high in these bioactive, antioxidant
properties e.g. concord grape juice(35) and wild blueberry
juice(36). However, some of these studies either had small,
potentially underpowered sample sizes, used a limited number
of cognitive tests to measure outcomes or had shorter
intervention durations therefore these results should be
interpreted with caution.
Nutrient and food supplementation
As mentioned, antioxidant compounds such as vitamins A, C
and E have a role in regulation of oxidative stress, a pathway
linked with neurodegeneration and cognitive decline(42).
However in this review, diet supplementation with vitamin
E(31) had no significant effect on progression from MCI to
dementia and/or AD or on cognitive function at intervention
completion. Furthermore, meta-analyses have reported no
significant effect of vitamin E on cognitive function
outcomes(43,44). The particular form of vitamin E used could
have an influence on the impact of this nutritional component
on cognitive decline, with research suggesting total tocopherol
plasma concentrations rather than single tocopherols may be
more valuable at predicting cognitive impairment, particularly
AD(45). Furthermore, as we consume foods in complex patterns,
resulting in ingestion of combinations of various forms of
vitamin E, it may be more beneficial to focus research efforts
away from single forms and follow a more holistic
investigation(15). In this review, supplementation with cocoa
flavonols(34) showed better cognitive performances for those
who received higher flavonols concentrations compared with
lower concentrations. There are suggestions in the literature
that flavonoids may exert their neuroprotective properties in a
similar mechanism to antioxidants in the body(46). However,
further indications suggest that flavonoids may have a more
prominent role in the regulation of neuronal signalling
pathways(47) or neuro-inflammation(48). It is clear that further
research is required to fully explore the mechanism of action of
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flavonoid compounds and investigate the potential role they
may have in protecting against cognitive decline(49).
Low folate and B vitamin status is linked to cognitive dys-
function during the ageing process and better cognitive per-
formances have been associated with higher intakes of B
vitamins(50–52). Furthermore, increased levels of homocysteine
have been linked to poorer cognition, particularly in memory
and attention(53–55). This may be explained by the role that
B vitamins have in one-carbon metabolic pathways in the
body, acting as co-factors for the remethylation of
homocysteine to methionine, producing the methyl-donor, S-
adenosylmethionine. This methyl donor has a specific role in
the methylation of phospholipids and neurotransmitters in the
brain, thus indicating how a depletion in B vitamins status
may influence cognitive function and ultimately, cognitive
impairment(56,57). In this review, supplementation with a B
vitamin combination(25) or with folic acid alone(24) had
significant effects on executive function(25) and furthermore,
when baseline homocysteine levels were elevated, there were
significant improvements in global cognition(25), memory(24,25)
and visuospatial skills(24). In support, not only have
improvements been observed in performance based cognitive
tests, B vitamin supplementation (folic acid, vitamin B6 and B12
combination) have resulted in reduced rates of brain atrophy in
MCI(58,59); a process which could result in progression to AD if
allowed to advance. However, findings are mixed with meta-
analyses of clinical trial data reporting no significant effect of B
vitamins on cognitive function(43,60). Therefore, further trial
research is warranted to confirm the role of B vitamins in
reducing cognitive decline.
PUFA have been associated with promoting cognitive func-
tion, primarily as a result of their anti-inflammatory proper-
ties(61). Furthermore, n-3 fatty acids, particularly DHA, are a key
component of neuronal membranes in the brain, influencing
neurogenesis and neuronal function(41,62). In this review,
supplementation with DHA+EPA(27,28) reported significant
improvements in the domain of memory, with DHA
supplementation alone(30) showing an additional
improvement in attention, albeit by a single cognitive test. In
contrast, evidence from meta-analyses have reported no
significant effect of n-3 fatty acids on cognitive
outcomes(43,62). Furthermore, it has been suggested that fatty
acid supplementation in individuals who are homozygous
carriers of the ApoE ε4 allele, a risk factor for cognitive decline,
could be resistant from the potential protective effects of fatty
acids on cognitive health(63). Thus, this is an important covariate
to consider when designing trials to test effectiveness of fatty
acid supplementation. However, some observational evidence
does exist to support the role of n-3 fatty acids in promoting
cognition with a study that followed non-demented participants
for 4 years, finding higher plasma EPA concentrations to be
associated with a lower incidence of dementia(64). In addition,
an intervention study with older adults with subjective memory
impairment investigated fatty acid supplementation
(EPA+DHA) v. maize oil placebo(65). Results showed
significantly improved cortical blood oxygen level-dependent
activity during a working memory task in the fish oil group
compared with placebo. In this review, one study investigating
DHA+EPA supplementation(29) found no effect on cognitive
function in comparison to control. A plausible explanation for
this finding could be that the placebo used this study was olive
oil, a component of the Mediterranean diet associated with
improved cognitive function owing to its anti-inflammatory
properties(66). Therefore, further investigation of the role of fatty
acids and cognitive decline is justified through well-designed,
robust studies.
Whole-foods/dietary patterns
Only three of the sixteen studies included in this review(12,37,38),
focused their diet intervention on ‘whole-foods/dietary patterns’
rather than single-nutrient supplements or single food products.
In everyday situations, individuals consume holistic dietary
patterns which involve complex interactions between
nutrients(67). It therefore could be suggested that the more
representative intervention design to measure the effects of diet
on cognition could be that which involved a dietary pattern
rather than focused on a single nutrient. In this review, however,
these studies were heterogeneous in terms of the dietary
intervention and reported mixed findings. Research evidence
suggests that ketogenic diets(68) and energy restriction(69) may
have a promising, yet under-investigated, role in AD prevention,
suggesting links to brain glucose metabolism(68), reduction in
oxidative stress(69) and anti-inflammatory mechanisms(69). There
is also emerging evidence from observational studies to suggest a
protective role for healthy dietary patterns such as the
Mediterranean diet on MRI measured brain structures(70–72) and
therefore further investigation of such dietary patterns is
necessary, with the inclusion of more rigorous assessment
measures, to help to provide insight into potential mechanisms
of how diet can impact brain health.
Use of biomarkers and cognitive markers
CSF biomarkers may be a valuable asset in detecting patholo-
gical changes in neurological diseases, owing to the processes
of extracellular amyloid-β deposition and accumulation of
hyperphosphorylated tau proteins(73). One study(38) in this
review included biomarker analysis in addition to cognitive test
measures. Increased concentrations of CSF Aβ42 were observed
in those with a MCI consuming a low diet (low saturated fat/low
GI) in comparison to healthy controls who observed a decrease
in CSF Aβ42 levels (online Supplementary material). Thus, CSF
biomarkers in this study changed in response to diet in aMCI
patients in the absence of any discernible changes in cognitive
function test scores, albeit in very small sample. These
differences could provide insights into the mechanisms of
action of β-amyloid in the body in cognitive impairment. In
particular, biomarker analysis may be more sensitive to dietary
changes and could be an important consideration for future
dietary intervention studies as the use of biomarkers could be a
more rigorous approach to assess cognitive performance in this
patient group(74). Furthermore, it has been suggested that the
use of brain imaging as a cognitive marker such as MRI
scanning is a more robust measure of cognition in comparison
to questionnaire based tests(50,75). In all, three studies in this
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review reported on cognitive marker information, including
MRI(30,33) and functional MRI imaging(32), as an additional
outcome measure for cognitive function, depicting some
significant interaction effects for the intervention group that
were not entirely reflected by cognitive function tests (online
Supplementary material). Brain imaging techniques have been
used in nutrition and cognition research, with investigations
into B vitamins utilising MRI scanning to detect changes in brain
atrophy in MCI(58,59), functional MRI scanning to explore fish oil
supplementation in older adults with subjective memory
impairment(65) as well as investigations of β-amyloid load
using positron emission tomography (PET) and neuronal
activity via PET imaging with 2-[18F]fluoro-2-deoxy-D-
glucose(76). Therefore, the use of these higher quality
methods could be implemented in future dietary intervention
trials to comprehensively measure the potential effects of diet
on cognition and explore mechanisms.
The mixed evidence found on the effect of diet on cognition
among MCI participants may be explained by the heterogeneity
of studies included, owing to variation in cognitive outcome
measures used, differences in the diet intervention type (sup-
plements v. single food products v. dietary patterns), variations
in sample size and duration of intervention. Furthermore, the
small number of dietary intervention studies conducted among
this patient group make it difficult to provide conclusive evi-
dence to support the effect of diet on cognitive outcomes. Of
the sixteen included studies, those with B vitamin and/or folic
acid supplementation(24,25), DHA/EPA supplementation(27,28,30)
or cocoa flavonol rich drinks(34) appeared to have the most
consistent effects on cognitive outcomes. However, it is difficult
to confirm that these dietary interventions are the most effective
in terms of promoting cognitive function due to the low number
of studies testing the same intervention. Nonetheless, the
outcomes of the systematic review highlight the need for
well-designed, robust RCT, with pretested and informed
methodological characteristics to further explore the role of
diet in cognitive decline.
Limitations
During the literature search for this review, a broad search
strategy was used to ensure the search covered all related
aspects to the reviews aims and objectives. However, search
limitations were set to only include studies in English language
and the grey literature was not included for this review, there-
fore this could have resulted in language and publication bias.
As RCT were the study design of choice for inclusion, this may
have caused selection bias. However, as RCT are considered
the best design for assessing the effect of a dietary intervention
with their ability to identify causality(77), this therefore provides
justification for the decision. Pilot studies were not included in
this review, as these studies are likely to have an underpowered
sample size. The number of studies included in this review were
small, however, as there are few RCT completed in this area,
this supports the need for further intervention studies to
increase the evidence-base. Due to the heterogeneity of
the included studies, the data were not meta-analysed.
Instead, a rigorous narrative review was implemented. Study
characteristics, such as short study durations, may have not
provided sufficient time to view a change in cognitive
outcomes. It has been suggested that long term, RCT are the
best approach in the design of a nutritional intervention to
measure cognitive performance, with estimations that the most
effect preventative trials require up to 3–5 years duration and
follow-up(78). Furthermore, ensuring a sufficient sample size
though determination by a power calculation will provide a
more stringent approach to the research design. Therefore, it is
important when designing intervention studies that duration
and sample size are pre-tested, though a feasibility study or by
comparison to similar studies in the field.
In all, eight of the sixteen studies in this review achieved the
maximum quality score as assessed by the Jadad scale(22).
Those studies who received the lowest scores failed to provide
details on the randomisation and blinding processes which took
place in the study. It is important to note however, as both
studies involved a dietary pattern intervention rather than a
supplement/placebo, it is impractical to ensure participants and
researchers are blinded to the intervention group. Therefore,
the decision that these studies are of ‘low quality’ is difficult to
confirm. Furthermore, for risk of bias, a number of studies were
allocated uncertain risk for selection, performance, attrition and
detection bias due to inadequate information on randomisation,
double blinding and/or withdrawals. Finally, a challenge within
this review was the heterogeneity of cognitive outcome
measures used to determine cognitive change. Some studies
grouped results by domain, while others by the single cognitive
tests used. This made it difficult when presenting the results of
this review, as some study results did not exactly fit within the
cognitive domains, as these were not specified in the original
paper. In line with the NIA-AA criteria for the diagnosis of
MCI(3), which state that for a diagnosis of MCI individuals must
have deterioration in one or more cognitive domains, it would
be beneficial for analysis purposes if future intervention studies
could assess cognition based on these domains to allow better
comparison of results. However, in saying that, even the tests
used to measure cognition within domains vary greatly and
there is a lack of standardisation. It is evident therefore, that
there is a demand to determine a specialised cognitive test
battery that can be used to measure change in cognition,
particularly within an MCI population. Furthermore, change in
cognition requires time, more rigorous examinations and
evaluation by clinical specialist(79). These are all important
considerations for future intervention trials going forward.
Conclusion
To date there is insufficient RCT evidence on the effect of whole
diets or specific dietary components on cognitive outcomes in
MCI patients. Existing studies are heterogeneous in terms of the
dietary intervention, duration, sample size and cognitive out-
come measures assessed, with the most consistent results for
cognitive function shown by B vitamins, folic acid, DHA and/or
EPA and cocoa flavonol supplementation. Further exploration
of the potential beneficial effect of diet on cognitive outcomes
in MCI is merited.
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